FDA Drug recall D-1292-2022
Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5…
- FDA Drug
- Class I
- terminated
- Published 2022-08-03
On 2022-08-03 the FDA classified a Class I recall of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5… by Mylan Pharmaceuticals, citing labeling: Missing label: Label missing from some prefilled pens.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1292-2022 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2022-07-05 |
| Published | 2022-08-03 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Mylan Pharmaceuticals |
| Distribution | US |
Product
Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons of 5 prefilled pens (NDC 49502-394-75), Rx only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV 15317, Manufactured for: Mylan Specialty L.P., Morgantown, WV
Reason
Labeling: Missing label: Label missing from some prefilled pens.
Identifiers
| code_info | Lot #: BF21002895, Exp. Date Aug 2023 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1292-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.